Journal Alzheimer's Research & Therapy is currently accepting research submissions for consideration in a special series on tau-based therapeutic strategies for Alzheimer's disease and related dementias.
There is reportedly great interest in finding therapeutics to reverse or remove tau aggregates from the human brain. Pathological aggregation of tau protein is associated with many neurodegenerative diseases, termed ‘tauopathies’, the most common of which is Alzheimer’s disease. However, there is currently only one drug entering phase III clinical trials for treating tauopathies.
This series aims to evaluate the current tau-based strategies developed to date, and to discuss new research directions and recommendations that will accelerate preclinical and clinical development of future therapies. The deadline for submissions is December 31, 2013.
The publication of research articles will be co-ordinated with a series of commissioned reviews and opinions written by leaders in the field and guest edited by Prof Leonard Petrucelli from Mayo clinic, USA.
Upcoming content includes a review on the potential synergy between tau aggregation inhibitors and tau chaperone modulators by Chad Dickey (USF), and a review of the Dominantly Inherited Alzheimer Network (DIAN) from the Principal Investigator and Program Director, John Morris (Washington University). Other contributors to the special series include Bradley Hyman (MGH), Leonard Petrucelli (Mayo clinic) and Melissa Murray (Mayo clinic).
An international peer-reviewed journal, Alzheimer’s Research & Therapy publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.
